^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Colorectal Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor) +
    Mekinist (trametinib) (MEK inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    The NCCN Panel recommends three drug combinations as subsequent treatment options for patients with mCRC that harbors the BRAF V600E mutation:...2) dabrafenib, trametinib, and cetuximab or panitumumab…
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO-GI 2023
    Title:

    Phase Ib study of dabrafenib, trametinib, irinotecan and cetuximab in BRAF V600E-mutated metastatic colorectal cancer.

    Published date:
    01/17/2023
    Excerpt:
    Dabrafenib, trametinib, irinotecan and cetuximab has tolerable toxicity and promising antitumor activity in BRAF V600E-mutated mCRC.
    Secondary therapy:
    irinotecan
    DOI:
    10.1200/JCO.2023.41.3_suppl.156